Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio

Autor: David Baanstra, Jyothis T. George, Bernard Zinman, Robert D. Toto, Uli C. Broedl, Christoph Wanner, Julio Rosenstock, Mark E. Cooper, Michael J. Pencina, Nikolaus Marx, Darren K. McGuire, Egon Pfarr, Michaela Mattheus, Maximilian von Eynatten, John H. Alexander, Vlado Perkovic, HJ Woerle

Publikováno v: Cardiovascular diabetology 17(1), 39 (2018). doi:10.1186/s12933-018-0682-3
Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-15 (2018)
Cardiovascular Diabetology

Background Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA® trial aims to evaluate the eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::654ec0031bc746ebe320e424607fd2b3

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

Autor: Maximillian von Eynatten, John H. Alexander, Christoph Wanner, Steven E. Kahn, Robert D. Toto, Nikolaus Marx, Julio Rosenstock, Egon Pfarr, David Baanstra, Darren K. McGuire, Michael J. Pencina, Odd Erik Johansen, Jyothis T. George, Vlado Perkovic, HJ Woerle, Thomas Meinicke, Bernard Zinman, Sven Schnaidt, Mark E. Cooper

Publikováno v: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 321(1), 69-79. AMER MEDICAL ASSOC

IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba5dc1aae78d293484ff3b82d37a22e2
https://doi.org/10.1001/jama.2018.18269

Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism

Autor: Ajay K. Kakkar, Clive Kearon, Janet Schnee, Sam Schulman, Samuel Z. Goldhaber, Sebastian Schellong, Patrick Mismetti, Henry Eriksson, David Baanstra

Publikováno v: Blood. 114:1-1

Abstract 1 Background. The direct oral thrombin inhibitor, dabigatran etexilate, has a predictable anticoagulant effect and may be an alternative to warfarin in patients with acute venous thromboembolism (VTE). Methods. In a randomized, double-blind,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a304a0bbd5ca7fe4e88cde1562da84a
https://doi.org/10.1182/blood.v114.22.1.1